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Among men, prostate cancer has a high prevalence, with relatively lower cancer-speciﬁc mortality risk compared to lung and colon
cancer. Prostate-speciﬁc antigen (PSA) screening has increased prostate cancer awareness since its implementation as a screening
tool almost 25 years ago, but, due to the largely indolent course of this disease and the unspeciﬁc nature of the PSA test, increased
incidence has largely been associated with cancers that would not go on to cause death (clinically insigniﬁcant), leading to an
overdiagnosis challenge and an ensuing overtreatment consequences. The overtreatment problem is exacerbated by the high risk
of side eﬀects that current treatment techniques have, putting patients’ quality of life at risk with little or no survival beneﬁt. The
goals of this paper are to evaluate the rise, prevalence, and impact of the overdiagnosis and ensuing overtreatment problems, as
well as highlight potential solutions. In this eﬀort, a review of major epidemiological and screening studies, cancer statistics from
the advent of prostate-speciﬁc antigen screening to the present, and reports on patient concerns and treatment outcomes was
conducted to present the dominant factors that underlie current challenges in prostate cancer treatment and illuminate potential
solutions.
1.Background
Accounting for 29% of all cancers in men, prostate cancer is
themost commoncanceramong menbehind nonmelanoma
skin cancer and is the second highest cause of cancer death
among men of all races [1, 2]. Over 2 million men currently
alive in the United States have had prostate cancer, and it
is estimated that 16.48% of men will be diagnosed with
prostatecanceratsomepointduringtheirlives[3].Estimates
of newly diagnosed prostate cancer cases hover near 240,000
for 2011 [4].
However prevalent, the incidence and mortality of pros-
tate cancer present very diﬀerently. It is estimated that 1
in 6 men will be diagnosed with prostate cancer but only
1 in 36 are expected to die because of it [5]. This may be
because it is predominantly diagnosed in more senior adults,
and, with a generally favorable outlook, men usually die
before any symptoms appear [1, 5]. To be sure, there are
tens of thousands of individuals who suﬀer the symptoms
of aggressive prostatic cancer, but, in terms of the larger
picture of prostate cancer, these men are well in the minority.
The question remains, why, for such a largely symptomless
condition, do so many incidental or nonmortal cancers get
diagnosed, and what does a diagnosis of cancer mean at this
clinically insigniﬁcant stage? The purpose of this paper is
to understand the trends that made such a predominantly
hidden cancer become so noticeable, highlight the burden
thatthisnowmarkedlyprevalentcancerplacesonhealthcare,
and illuminate current developments that may hold promise
for easing that burden.
2. PSA Test IncreasesIncidence
The primary reason for such a high rate of diagnosis for
so often a symptomless condition is most likely the result
of prostate-speciﬁc antigen (PSA) screening practices which
came about in the late 1980s following studies which seemed
to demonstrate the value of PSA as a biomarker for prostate
cancer [6–8]. The 1987 study by Stamey and colleagues was
perhapsthemostdominantoneduetoitscitationprevalence
in Medline [9, 10]. In 2004, however, Stamey and colleagues2 Advances in Urology
maintained that PSA was only an accurate reﬂection of
prostate cancer circa 1985 and that it was only demonstrated
a relation to benign prostate hyperplasia throughout the ﬁve
yearsprecedingtheirnewerstudy[11].Moreover,Thompson
and colleagues demonstrated in 2005 that there was no
single PSA cutoﬀ that could yield both high sensitivity and
speciﬁcity [12].
Nevertheless, early studies of PSA testing exhilarated the
scientiﬁc community by oﬀering the prospect of early detec-
tion of prostate cancer, a disease so often diagnosed late in its
development due to its often symptomless progression [13,
14].TheuseofPSAscreening increasedrapidlyin theUnited
States after 1987, resulting in a dramatic change in annual
prostate cancer incidence and, in turn, a sharp increase in
prostate cancer treatment both in the United States and
abroad [15–17]. But while more cancers were being found
and treated, the prostate cancer speciﬁc mortality rate only
modestly decreased until 1993, after which little change was
seen [15, 18]. Figure 1 from the National Cancer Institute
shows this rising incidence of prostate cancer in contrast to
the relatively unchanged mortality rate from 1975 to 2007.
The disparity continues today, where the number of newly
discovered prostate cancers is over seven times the number
of prostate cancer related deaths [2].
3. PSATest CreatesStage Migration
What may account for this is the fact that, while helping
to discover mortal cancers, PSA testing also often led to
the discovery of nonmortal cancers, or those which would
never have been given notice in the absence of screening
[19]. Given that 20–50% of asymptomatic men are found
to harbor prostate cancer upon autopsy, it follows that the
PSA test, with only a 24.1% positive predictive value, leads
to a much greater detection of cancers, both mortal and
nonmortal [20–23]. It is also possible that widespread PSA
testing and treatment may have slowly weeded out the more
dangerous prostate cancers from the population. Whether
from increased testing, increased treatment of dangerous
cancers, or some combination of the two, more cancers were
being found at lower stages from 1986 to 1993, with tumors
often being low grade, clinically localized, and/or organ
conﬁned. From 1993 to 2003, there was a 75% reduction in
the proportion of metastatic diagnoses for prostate cancer
[24]. The link between PSA testing and stage migration was
documentedinAustriaduringalarge-scalePSAtestingstudy
and again later in the United States [24–26]. This seems
to indicate that as PSA testing continues, prostate cancer
will also continue to be diagnosed at clinically insigniﬁcant
stages.
4. Overdiagnosis Ensues
Given the propensity of PSA testing to detect cancers both
mortal and nonmortal, overdiagnosis was a probable out-
come. Overdiagnosis due to PSA testing has been doc-
umented extensively through epidemiological studies and
computerized models, at rates which range from 29% in
speciﬁc regions to an estimated 80% should all men in the
United Statesbe screened[7,27,28].Progress hasbeen made
in investigating diﬀerent biomarkers and variations of PSA
testing for early detection of mortal prostate cancer, but,
despite its ﬂaws, the PSA test still remains the best screening
tool currently available, suggesting continued overdiagnosis
[29–31].
5.UncertaintyLeadstoTreatment
The corollary of the overdiagnosis problem is an overtreat-
ment problem. While active surveillance (AS) might seem
the best course of action for many due to the relatively low
mortality rate and exceedingly high 15-year survival rates of
prostate cancer, working against that is a lack of consensus
on what the inclusion criteria should be for AS, what the
optimal follow-up schedule should be, or even how to best
deﬁne progression [32]. For instance, the Epstein criteria
is one common method of establishing whether or not a
cancer is clinically insigniﬁcant, and this relies on a third or
less of biopsy cores being positive, 50% or less involvement
of any 1 core, and a PSA density of less than 0.15ng/mL.
However, the D’Amico criteria, also widely used, calls for a
Gleason score of six or less, a PSA of less than 10ng/mL,
and a T1 clinical stage. Studies have shown highly favorable
results for certain criteria, like the 100% 10-year prostate
cancer-speciﬁc survival rate documented by researchers who
took patients oﬀ AS based on PSA doubling time [33].
Other studies suggest that PSA kinetics are not reliable for
AS inclusion/exclusion criteria [34]. In yet another study,
researchersfoundthatprostatespecimensﬁttingsixdiﬀerent
inclusion criteria for clinically insigniﬁcant disease would
havebeenmisclassiﬁed14–27%ofthetimebasedonGleason
8 ﬁndings [35]. Research continues to reﬁne AS criteria, but
a clear understanding of how to deﬁne clinically insigniﬁcant
disease has not been reached.
The lack of consensus and the thought of harboring a
cancer with an unpredictable progression leads to feelings
of uncertainty in the patient, in turn arousing high levels
of emotional distress, anxiety, and depression [36]. While
support services can assist in ameliorating the psychological
distress, men with prostate cancer tend to avoid disclosure
and are unlikely to utilize health and psychological support
services [37]. At the same time, doctors tend to underes-
timate the psychological morbidity of men with prostate
cancer, leading to a lack of provider referral [38].
W i t hal a c ko fs o c i a ls u p p o r t ,m o t i v a t i o nt os e e ki to u t ,
or provider referrals to address the psychological discomfort
associated with prostate cancer, most newly diagnosed men
suﬀer the full psychological burden of living with an
unpredictable cancer. This proves too much to bear, as rather
than learning to live with what is most likely a nonmortal
cancer, men elect various courses of treatment to escape the
mental anguish of uncertainty. In a study of the reasons for
undergoing various treatment types, Gwede et al. found that
44% of men chose radical prostatectomy primarily because
they believed it to be their best chance to be cured [39].Advances in Urology 3
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Figure 1: Change in prostate cancer incidence and mortality from 1975 to 2007 documented by the National Cancer Institute. arates
are age adjusted to the 2000 US Std Population (19 age groups—Census P25-1103). Regression lines and APCs are calculated using the
Joinpoint Regression Program Version 3.5, April 2011, National Cancer Institute. The APC is the annual percent change for the regression
line segments. The APC shown on the graph is for the most recent trend. The APC is signiﬁcantly diﬀerent from zero (P<0.05).
Denberg et al. found that a group of men underwent
surgery due to the belief that it was the most certain, expe-
ditious, and tangible option and that, even though it might
reveal that a tumor escaped the prostate, it would at least
eliminate some uncertainty. These same men found no
other option appealing because they dealt with acting on a
hidden and unseen cancerous organ. Even those who did
not choose surgery in the Denberg study were motivated
by uncertainty, in their case, they were trying to avoid
the uncertainties associated with surgery. It should also
be noted that half of their patient sample avoided seeking
second opinions due to delay, prolonged uncertainty, and
feelings of increased anxiety [40]. Similar ﬁndings were
reported in England, Scotland, and Whales, where a study
of 50 men with early-stage prostate cancer found reasons
for prostatectomy ranging from frustration with the lack of
concrete information and consensus over what to do, to the
explicit desire to ﬁx the problem [41].
The uncertainty and anxiety of having prostate cancer
are certainly a formidable driver for treatment instead
of AS, and researchers have documented it as a valuable
predictor of treatment receipt [42, 43]. Watchful waiting
(often synonymous with AS) is often used in other countries
but rarely in the United States, especially for younger men
with early-stage prostate cancer for whom treatment is often
advocated [44]. When briefed with speciﬁc cancer statistics
and information on the side eﬀects of treatment, most
patients place little weight on side eﬀects when there is even
a chance of prolonged survival [45]. Mazur and Hickam
showed that even when attempting to bias patients against
surgical therapy by explicitly naming surgical complications
andpresentingratesofthosecomplicationshigherthanwhat
was typically in the literature, most patients still preferred
surgical treatment over AS for localized prostate cancer [46].
Research shows that, on the whole, only 18.5% forgo active
treatment for watchful waiting, all in the face of a cancer that
is lethal in only 1 in 32 cases [47].
6. Prevalence of Overtreatment
The amount of treatment received is certainly dispro-
portional, and studies clearly indicate that a substantial
proportion of treatments do not go on to prevent death
from prostate cancer. The European Randomized Study for
Prostate Cancer (ERSPC) reported, for instance, that 1410
menneededtobescreenedand48treatedtoprevent1cancer
death [48]. Results from the Randomized Scandinavian
Prostate Cancer Group Study show that an estimated 15
patients needed to be treated to avert one death at 15 years
and that, for adjuvant radiation therapy, the number of
patients needed to be treated to avert one death at 12.6 years4 Advances in Urology
was 9.1 [49]. Perhaps the most favorable results were found
in Quebec, where out of an estimated 100 men with screen-
detectable prostate cancer, an average of 16 could have their
livesextendedbysurgery(shouldthosemenbefoundbyway
ofextensivescreeningeﬀorts)[50].However,themostrecent
data comes from the Prostate Cancer Intervention versus
ObservationTrial(PIVOT),whichreportsthat,after12years
of followup, overall prostate cancer mortality was only 3%
lower for men having radical prostatectomy. In fact, men
with low-risk prostate cancer were actually shown to have
a 2.4% better survival rate with watchful waiting than with
surgery. PIVOT reports that, even when looking exclusively
at cases of intermediate risk, radical prostatectomy still only
achieves a 4.8% better survival rate [51].
The statistics from these studies also do not take into
account the copious amounts of unnecessary biopsies that
would have to be performed to ﬁnd these cancers in the ﬁrst
place, as in order to detect even 83.4% of cancer cases by
PSAtesting,acalculated61.1%ofmenwithoutcancerwould
need to be subjected to prostate biopsy, a procedure that is in
itself not without consequence to quality of life [12].
In an eﬀort to quantify the amount of overtreatment
stemming from prostate cancer, Welch and Albertsen used
Surveillance Epidemiology and End Results (SEER) data
from the National Cancer Institute and statistics from the
US Census to estimate that from 1986 to 2005, 1,004,800
of an additional 1,305,600 overdiagnosed cancers received
treatment, with 571,000 excess prostate-cancer-related surg-
eries, and 477,400 excess prostate-cancer-related radiation
treatments [10].
7. Side Effects of Treatment
Excess treatment brings excess side eﬀects, and, in the case
of prostate cancer, they are not uncommon. Overtreated
patients run several risks, especially when it comes to radical
prostatectomy and/or radiation therapy, the most domi-
nant treatment options. The US Preventative Services Task
Forces reviewed the most common side eﬀects of treatment
from 1994 to 2002, bringing the problems associated with
overtreatment to light. Long-term adverse eﬀects of radical
prostatectomy, for instance, were sexual dysfunction (20–
70%) and urinary incontinence (15–50%). For electron
beam radiation therapy, approximately 45% could expect
erectiledysfunction,2–16%urinarydysfunction,and6–25%
bowel dysfunction. For Androgen Deprivation Therapy
(ADT), approximately half of patients who were sexually
active beforehand were not sexually active afterward, 5–25%
had breast swelling, and 50–60% had hot ﬂashes along
with other potential long-term complications like anemia
and osteoporosis. For brachytherapy, a majority of men
reported having distressing urinary symptoms, 21–36%
reported decreased erectile function, 18% diarrhea, and 19%
persistent rectal bleeding [52].
The primary concern of most men undergoing radical
prostatectomy is preservation of potency, and, to that
end, bilateral nerve sparing techniques in younger cohorts
(median age 57) have yielded a potency rate as high as 86%,
with more typical results hovering around 44–76% [53]. The
second most dominant concern is urinary continence, but
data on that is diﬃcult to generalize given the changing
deﬁnitionofcontinencewhichvariousstudiesemploy.When
urinary continence is deﬁned as not needing protection to
keep outer garments dry, 93% of men followed for more
than 18 months recovered continence, but, when using total
urinary control as a benchmark, only 32% of men were con-
tinent at 24 months [53]. Among patients in the Rotterdam
section of the ERSPC who underwent radical prostatectomy,
as much as 80–90% reported erectile dysfunction and 39–
49% reported urinary incontinence [54]. Studies analyzing
even the most advanced minimally invasive prostatectomy
techniques (robotic and/or laparoscopic) ﬁnd continence
ranging 68.0–94.7%, potency 33.3–65.3%, and progression-
free survival 84.1–92.0% [55].
In more recent ﬁndings, these problems are still preva-
lent. In a comparison of 1938 men who received minimally
invasive radical prostatectomy and 6899 men who received
open retropubic radical prostatectomy, investigators found
incontinence rates of 15.9 and 12.2 per 100 person-years,
respectively. Sexual dysfunction was higher, however, with
rates of 26.8 and 19.2 per 100 person-years, respectively
[56]. Another large-scale study of 1,201 patients treated with
surgery, brachytherapy, or EBRT found erectile dysfunction
rates two years posttreatment of 57%, 31%, and 35%,
respectively [57, 58].
8. Focal Therapy Offers a Solution
The aforementioned statistics indicate that the majority of
these treatments will infer no survival beneﬁt in the ﬁrst
place, so the amount of men who go on to suﬀer such
side eﬀects is certainly unwarranted. However, without an
established and reliable way to distinguish mortal from
nonmortalcancersandtheoverwhelmingpreferencebyboth
patients and providers to pursue treatment options in the
face of such uncertainty, it seems treatment will continue
to be the dominant option. Fortunately, focal therapy
techniques developing since the 1990s are now showing
promise as a method of treatment which is not associated
with such arresting rates of side eﬀects. These techniques
avoid the costs that other techniques would require in order
to reduce side eﬀects to comparable levels while still being
eﬀective [59].
Clinical trials have demonstrated the feasibility of focal
ablative methods using high-intensity focused ultrasound
and cryosurgery [60], and focal techniques are expected to
improve as imaging techniques allow for better pathological
assessments[61–63].Successfulfocaltherapydemandsstrin-
gent selection factors, and this requires an imaging modality
which can accurately characterize the location, extent, and
grade of a patient’s prostate cancer [64]. In this eﬀort,
a brachytherapy template-guided transperineal saturation
biopsy technique (3DMB) was described and tested by
Crawfordetal.onprostateautopsyspecimensin2005,which
demonstrated both feasibility and increased accuracy over
sextant biopsies [65]. In evaluating the potential of 3DMB inAdvances in Urology 5
vivo, Barqawi et al. compared previous TRUS results of 215
patients to those obtained using 3DMB, ﬁnding new cancer
foci in 82 patients and higher Gleason scores in 49 patients,
demonstrating a potentially signiﬁcant improvement in the
way prostate cancer can be evaluated [66]. While long-term
results have not been disseminated as of yet, we are currently
anticipating the publication of 5-year follow-up data on
patients treated with focal cryoablation in conjunction with
3DMB.
While promising results continue to be seen, there are
still hurdles to overcome, such as the issue of gland stabiliza-
tionduringtreatment,orhowtoworkaroundlargeprostates
when employing 3DMB [67]. In addition, wide variability
in patient selection, disease characterization, and treatment
protocols still exist. A preferred ablative energy for focal
therapy has also not been conferred (cryosurgery, high-
intensity focused ultrasound, vascular-targeted photody-
namic therapy, brachytherapy, radiotherapy, or tomother-
apy), yet it seems that one of the dominant concern for those
investigating this approach has to do with standardizing
follow-up protocols and creating reliable and meaningful
outcomes measures to evaluate it, as the PSA measurements
so often relied on to assess other forms of treatment are
not only unreliable as mentioned, but also tend to take on
diﬀerent meaning when larger portions of the organ are
left intact, as is the case with focal therapy [68, 69]. While
biochemical disease-free status using American Society of
Therapeutic Radiation Oncology or Phoenix criteria seems
to be the dominant means of evaluating focal treatment,
standardized algorithms for determining success would be of
signiﬁcant beneﬁt to researchers pursuing long-term follow-
up studies on focal therapy. Standardization should be a
primary focus of future follow-up studies and will serve
greatly in conferring the eﬃcacy of diﬀerent methods and
identifying areas for improvement.
9. Conclusion
While procedural advances and screening eﬀorts continue to
report improvements, the PSA test is still the best screening
tool currently available, and this suggests a continuing trend
of overdiagnosis based on historical data. Early detection of
prostate cancer is possible, but early discrimination is not,
leading to a great deal of uncertainty as to whether or not
a particular patient’s prostate cancer will become aggressive.
The psychological burden that comes with this uncertainty
more often than not leads to treatment regardless of patients’
understanding of high risks of side eﬀects and low survival
beneﬁt rates. Whether or not improved screening or imaging
techniques will be able to better distinguish nonmortal from
mortal cancers remains to be seen, as well as what role that
will play in regards to the psychological distress that comes
with being diagnosed with prostate cancer.
With overwhelming evidence, the root of overtreatment
and the unnecessary side eﬀects that ensue lie in the
psychological burden of dealing with uncertainty and with
the lack of emotional support or the motivation to seek
it out, the vast majority of newly diagnosed men undergo
serious treatment eﬀorts regardless of the potential for
harmful side eﬀects. Solutions to the overtreatment problem
may come from enhanced screening and imaging eﬀorts or
the delivery and implementation of psychological care for
those diagnosed with localized cancer. More likely, solutions
will come from improvements in treatment methodol-
ogy. Focal therapy appears to be a promising avenue in
this regard as it is noninvasive, has fewer side eﬀects,
and remains more cost-eﬀective than side-eﬀect reducing
advanced radiation and robotic techniques. Moreover, focal
therapy does not exclude the possibility of more radical
options and does not necessarily replace traditional tech-
niques. Enhanced methods to evaluate focal therapy and
standardized protocols to assess outcomes measures will
help progress this emerging practice as improvements in
imaging modalities help practitioners realize its assumed
potential.
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